| Literature DB >> 30867256 |
Yan Huang1, Xiao-Ying Lou1, Ya-Xi Zhu1, Yu-Chen Wang2, Lei Zhang3, Hai-Ling Liu1, Chao Wang1, Huan-Miao Zhan1, Zhi-Qiang Cheng1, Wei-Yan Tan1, Lei Wang4, Xin-Juan Fan5.
Abstract
Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is the standard treatment for locally advanced rectal cancer. Here, we analyzed the impact of local and systemic environments on the tumor response to preoperative chemoradiotherapy in rectal cancer. We recruited 141 patients with rectal cancer treated with nCRT. We evaluated the local tumor environment, including tumor-infiltrating lymphocytes (TILs), intratumor budding (ITB), and the systemic inflammatory environment, including the neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein (CRP) level. Our finding revealed that tumor regression was significantly associated with the density of CD8+ TILs in the intraepithelial, the presence of ITB, the combination of NLR and CRP (NLR-CRP) value, and the combination of CD8+ intraepithelial TIL (iTIL) density and ITB presence. Moreover, multivariate analysis showed that only the combination of CD8+ iTILs and ITB was an independent predictive factor for the pathological response to nCRT in rectal cancer. Our finding demonstrate that the local tumor environment was a better predictor of the tumor response than the systemic environment and thus provided new insight into screening for patients who are more likely to benefit from cancer treatment.Entities:
Keywords: neoadjuvant chemoradiotherapy; rectal cancer; tumor budding; tumor regression grade; tumor-infiltrating lymphocytes
Mesh:
Substances:
Year: 2019 PMID: 30867256 PMCID: PMC6434387 DOI: 10.1042/BSR20190003
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
Figure 1The expression of CD8 and CD4 in rectal cancer
Immunohistochemical staining of CD8+ and CD4+ T cells in biopsy samples of rectal cancer before nCRT at a low density (A; left panels, ×100; right panels, ×400) and a high density (B; left panels, ×100; right panels, ×400). In each subgroup, the right panels display a representative enlarged view from the area shown in the left panels. The iTILCD8 (a1, a2) and sTILCD8 (b1, b2). The iTILCD4 (c1, c2) and sTILCD4 (d1, d2). One representative staining example is shown.
Abbreviations: iTILCD4, tumor-infiltrating CD4+ lymphocytes in the intraepithelial; iTILCD8, tumor-infiltrating CD8+ lymphocytes in the intraepithelial; sTILCD4, tumor-infiltrating CD4+ lymphocytes in the stromal compartment; sTILCD8, tumor-infiltrating CD8+ lymphocytes in the stromal compartment.
Figure 2H&E-stained biopsy samples of rectal cancer before nCRT
Rectal cancer without tumor budding (a1, ×100; a2, ×400) and with tumor budding (b1, ×100; b2, ×400)
Correlation of TRG with TILs and serological markers
| Response to nCRT | |||
|---|---|---|---|
| Good ( | Poor ( | ||
| Age | |||
| ≥60 | 22 | 31 | 0.744 |
| <60 | 39 | 49 | |
| Gender | |||
| Male | 45 | 54 | 0.420 |
| Female | 16 | 26 | |
| TNM stage | |||
| Stage II | 9 | 21 | 0.098 |
| Stage III | 52 | 59 | |
| Presence of ITB | |||
| Yes | 7 | 19 | 0.048 |
| No | 54 | 61 | |
| iTILCD4 | |||
| ≥1 | 3 | 12 | 0.54 |
| <1 | 58 | 68 | |
| sTILCD4 | |||
| ≥41 | 37 | 40 | 0.208 |
| <41 | 27 | 40 | |
| iTILCD8 | |||
| ≥4.5 | 48 | 38 | <0.001 |
| <4.5 | 13 | 42 | |
| sTILCD8 | |||
| ≥ 42.5 | 35 | 34 | 0.080 |
| <42.5 | 26 | 46 | |
| CEA | |||
| ≥2.84 | 22 | 44 | 0.026 |
| <2.8 | 39 | 36 | |
| CA199 | |||
| ≥7.15 | 37 | 61 | 0.046 |
| <7.15 | 24 | 19 | |
| NLR | |||
| ≥2.48 | 8 | 18 | 0.083 |
| <2.48 | 53 | 62 | |
| CRP | |||
| ≥2.74 | 19 | 33 | 0.145 |
| <2.74 | 42 | 47 | |
| NLR-CRP | |||
| High | 21 | 43 | 0.022 |
| Low | 40 | 37 | |
| iTILCD8+ and ITB 2 groups | |||
| iTILCD8 high and without ITB | 40 | 21 | <0.001 |
| iTILCD8 high and with ITB/ | 24 | 56 | |
| iTILCD8 low and without ITB/ | |||
| iTILCD8 low and with ITB | |||
P<0.05. Abbreviations: CA199, carbohydrate antigen 199; iTILCD4, tumor-infiltrating CD4+ lymphocytes in the intraepithelial; iTILCD8, tumor-infiltrating CD8+ lymphocytes in the intraepithelial; sTILCD4, tumor-infiltrating CD4+ lymphocytes in the stromal compartment; sTILCD8, tumor-infiltrating CD8+ lymphocytes in the stromal compartment.
Clinicopathological characteristics of patients
| Age, mean (SD) | 54 |
| Sex, | |
| Male | 99 (70%) |
| Female | 42 (30%) |
| TNM stage, ( | |
| Stage II | 30 (21%) |
| Stage III | 111 (79%) |
| TRG, (n%) | |
| 0 | 27 (19%) |
| 1 | 34 (24%) |
| 2 | 61 (43%) |
| 3 | 19 (14%) |
| Presence of ITB | |
| Yes | 26 (18%) |
| No | 115 (82%) |
The sTILCD8 and sTILCD4 in NLR-CRP low group (n=77)
| Response to nCRT | |||
|---|---|---|---|
| Good ( | Poor ( | ||
| sTILCD8 | |||
| High | 24 | 14 | |
| Low | 16 | 23 | 0.043 |
| sTILCD4 | |||
| High | 28 | 1 | 0.32 |
| Low | 12 | 20 | |
Abbreviations: sTILCD4: tumor infiltrating CD4+ lymphocytes in stromal compartment; sTILCD8: tumor infiltrating CD8+ lymphocytes in stromal compartment.
P<0.05.
The sTILCD8 and sTILCD4 in NLR-CRP high group (n=64)
| Response to nCRT | |||
|---|---|---|---|
| Good ( | Poor ( | ||
| sTILCD8 | |||
| High | 11 | 20 | 0.659 |
| Low | 10 | 23 | |
| sTILCD4 | |||
| High | 11 | 21 | 0.790 |
| Low | 10 | 22 | |
Abbreviations: sTILCD4: tumor infiltrating CD4+ lymphocytes in stromal compartment; sTILCD8: tumor infiltrating CD8+ lymphocytes in stromal compartment.
Multivariate analyses for predictors associated with TRG
| OR | 95% CI | ||
|---|---|---|---|
| Age | −0.006 | −0.173 to 0.160 | 0.941 |
| Sex | 0.075 | −0.099 to 0.249 | 0.395 |
| TNM stage | 0.099 | 0.300 to 0.101 | 0.329 |
| sTILCD4 | 0.051 | −0.115 to 0.216 | 0.546 |
| CA199 | −0.096 | −0.278 to 0.086 | 0.298 |
| CEA | −0.106 | −0.274 to 0.016 | 0.211 |
| NLR | −0.001 | −0.288 to 0.286 | 0.993 |
| CRP | −0.006 | −0.387 to 0.374 | 0.974 |
| NLR-CRP | −0.136 | −0.567 to 0.295 | 0.534 |
| sTILCD8 | 0.052 | −0.128 to 0.231 | 0.570 |
| iTILCD8+ and ITB | 0.273 | 0.095 to 0.451 | 0.003 |
P<0.05.Abbreviations: CA199, carbohydrate antigen 199; sTILCD4: tumor infiltrating CD4+ lymphocytes in stromal compartment; sTILCD8: tumor infiltrating CD8+ lymphocytes in stromal compartment.